SM 99% Freeze-dried powder SM In stock Minimum Order
496 Inquiries
910463-68-2
Industrial Grade
99%
China
KZY
2mg/5mg/10mg/15mg/20mg/30mg/vials;10 vials/Box
2026-09-05
Retatrutide,Tirzepatide,Samaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionSemaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes.Basic Info
-
Product Name:
Semaglutide
Other Name:Sermaglutide;Semaglutide impurity;Sermaglutide USP/EP/BP;semaglutide;Sermaglutide CAS 910463 68 2;Semaglutide (H-7894.0001);semgalutide;Semaglutide Injection
CAS No.:910463-68-2
Molecular Formula:C187H291N45O59
InChIKeys:DLSWIYLPEUIQAV-CCUURXOWSA-N
Molecular Weight:4113.57754
Exact Mass:4113.122087 g/mol
EC Number:203-405-2
Color/Form:White to off-white
Categories:
Characteristics-
PSA:
1650 Ų
XLogP3:5.44520
Critical Temperature & Pressure:Store at -20°C
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Samaglutide
-
Location:
Room 205, Sanyuanli Avenue, Baiyun District, Guangzhou City
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2026
-
-
Inquiry History496 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Weight Loss Semaglutide intermediate 99% White powder COA High Quality peptide GLP-1 910463-68-2
5 MG Apr 11, 2024
United States
Gene-Biocon Semaglutide 910463-68-2 GLP-1analogs diabetes weight loss 96% White or off-white powder
2 Dec 5, 2023
United States
Semaglutide 910463-68-2
1 G Sep 21, 2023 
United Kingdom
Semaglutide 910463-68-2 Muhuang
100 G Aug 18, 2023 
China
Semaglutide CAS 910463-68-2
1 KG Apr 16, 2026
United States
Sermaglutide 99% 910463-68-2
2 KG Oct 21, 2023
United Kingdom
TGYFactory Supply Semaglutide Peptide 99% CAS 910463-68-2
50 MT Nov 13, 2023 
Sri Lanka
Bulk Supply 98% up Sermaglutide powder CAS 910463-68-2
300 G Nov 18, 2023
United States
Semaglutide Ozempic Sermaglutide 99.9% white powder 910463-68-2 Teruiop
500 G Oct 9, 2023
United States
Raw mateiral Semaglutide CAS 910463-68-2 99% White powder
1000 G Sep 23, 2023
United States
10MG vial pack Semaglutide 99% 910463-68-2 GLP-1 Peptide
10 MT Oct 18, 2023 
Switzerland
Semaglutide Ozempic Sermaglutide 99.9% white powder 910463-68-2 Teruiop
5000 MT Sep 13, 2023
United States
High Purity Peptide Semaglutide 910463-68-2 With Safe Shipping
1 G Sep 7, 2023
United States
High Purity IGF-1 LR3 Peptide CAS 910463-68-2 IGF1 LR3
60 MG Aug 4, 2025
China
Semaglutide Tirzepatide for Weight Loss CAS: 910463-68-2 Retatrutide Cagrilintide
1 MT Jul 5, 2025
United States
High Purity IGF-1 LR3 Peptide CAS 910463-68-2 IGF1 LR3
10 MT Sep 19, 2025
United States
High Purity IGF-1 LR3 Peptide CAS 910463-68-2 IGF1 LR3
2 Nov 13, 2024
United States
semaglutide CAS 910463-68-2 in stock 2-4 days safe delivery
1 MT Nov 4, 2023
United Kingdom
API Pharmaceutical Chemical Grade Raw Materials CAS 910463-68-2 Semaglutide
40 MT Sep 27, 2023
United States
High Purity IGF-1 LR3 Peptide CAS 910463-68-2 IGF1 LR3
10 Sep 27, 2023 Post an enquiry for this product
